NAROPIN

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Hong Kong SAR China, Ireland, New Zealand, Singapore, South Africa, UK.

Active ingredients

The drug NAROPIN contains one active pharmaceutical ingredient (API):

1	Ropivacaine UNII V910P86109 - ROPIVACAINE HYDROCHLORIDE
	Ropivacaine is a long-acting amide-type local anaesthetic with both anaesthetic and analgesic effects. At high doses ropivacaine produces surgical anaesthesia, while at lower doses it produces sensory block with limited and non-progressive motor block.
	Read more about Ropivacaine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NAROPIN Solution for injection	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N01BB09	Ropivacaine	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides
Discover more medicines within N01BB09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	505618010042017, 505618010042117, 505618010042217, 505618010042317
CA	Health Products and Food Branch	02229411, 02229415, 02229418
GB	Medicines & Healthcare Products Regulatory Agency	46953, 50324, 50328, 50330
HK	Department of Health Drug Office	42881, 42882, 42883
NZ	Medicines and Medical Devices Safety Authority	6427, 6428, 6429, 8801, 9739
SG	Health Sciences Authority	09262P, 09264P
US	FDA, National Drug Code	52584-286, 63323-285, 63323-286, 63323-287, 63323-288
ZA	Health Products Regulatory Authority	31/4/0124, 31/4/0125, 31/4/0127, 35/4/0409